NuMat Medtech, formed from the merger of Sanifit Medtech and NuMat Biomedical, develops novel implant coatings (including NM_973 and NM_977) intended to improve bone integration and reduce infections. The company was born in 2016 and is based in Palma de Mallorca (Baleares). Leadership includes Toni Caldentey as CEO, Marta Monjo as scientific director, and Joana Maria Ramis as laboratory director. The funds from the latest round will finance preclinical studies of NM_973 and NM_977 applied to implants currently on the market and aim to reinforce strategic alliances with international dental and orthopedic industry players. Financially, NuMat completed a small €150,000 financing in May 2017 and has now closed a larger €530,000 round. The company’s cap table after the operation comprises about 20 shareholders, including the founders of Sanifit Medtech and NuMat Biomedical.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2018